Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12651764.
- Also identified by PMC identifier 1719511.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the case of an 8 week old infant with fulminant autoimmune haemolytic anaemia refractory to conventional immunomodulating treatment. Massive haemolysis resulted in cardiac decompensation and acute renal failure which necessitated mechanical ventilation and peritoneal dialysis. Rituximab, a chimeric anti-CD20 monoclonal antibody, halted progression of the haemolytic process, but the patient died of acute viral pneumonia and disseminated fungal infection. Earlier introduction of rituximab might have prevented the renal complications. Paediatricians should be aware of this useful therapeutic tool for treatment of refractory autoimmune haemolytic anaemia and balance its use against the risk of potential life threatening infection.
Medical subject headings
- Anemia, Hemolytic, Autoimmune
- Antibodies, Monoclonal
- B-Lymphocytes
- Immunosuppressive Agents